期刊
SEMINARS IN HEMATOLOGY
卷 49, 期 3, 页码 207-214出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminhematol.2012.04.007
关键词
-
类别
Proteasome inhibition is a validated therapeutic strategy for the treatment of B-cell neoplasms. The peptide boronate based inhibitor bortezomib has become an important tool in the armamentarium for the treatment of multiple myeloma (MM) and has spurred the development of new agents that target the catalytic activities of the proteasome. Five of these agents, representing three distinct chemical classes, have reached clinical testing. These compounds have properties similar to and distinct from bortezomib. Here, the preclinical activity and clinical development of these agents are reviewed with special attention given to comparisons with bortezomib. Semin Hematol 49:207-214. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据